1566 studies found for:    "Ovarian Neoplasms"
Show Display Options
Rank Status Study
21 Terminated Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab;   Drug: Revlimid, Doxil, Avastin
22 Recruiting Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Conditions: Ovarian Diseases;   Ovarian Neoplasms
Interventions: Other: Laboratory Tumor Marker Analysis;   Other: Transvaginal Ultrasound;   Other: Health Status Questionnaire
23 Completed DOXIL for Consolidation Therapy in Ovarian Cancer.
Condition: Ovarian Neoplasm
Intervention: Drug: liposomal doxorubicin
24 Completed A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Conditions: Ovarian Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
25 Recruiting Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Conditions: Recurrent Ovarian Cancer;   Platinum Sensitive Ovarian Cancer
Intervention: Drug: Carboplatin
26 Active, not recruiting Lymphadenectomy In Ovarian Neoplasms
Condition: Ovarian Cancer
Interventions: Procedure: No Lymphadenectomy  (LNE);   Procedure: Lymphadenectomy  (LNE)
27 Withdrawn N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
Conditions: Ovarian Carcinoma, Stage 3 or 4;   Epithelial Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel;   Drug: N-acetylcysteine;   Drug: Cisplatin
28 Completed Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Drug: OSI-211 (Liposomal Lurtotecan)
29 Recruiting [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
Condition: Ovarian Neoplasm
Intervention: Drug: Pazopanib and paclitaxel
30 Completed 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients
Conditions: Ovarian Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Pancreatic Neoplasms;   Digestive System Neoplasms;   Digestive System Diseases;   Pancreatic Diseases
Intervention: Drug: 89Zr-MMOT0530A
31 Terminated Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Conditions: Neoplasms;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866;   Drug: Gemcitabine and Carboplatin;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin
32 Completed A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
Condition: Ovarian Neoplasm
Interventions: Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Cisplatin;   Drug: G-CSF
33 Completed A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)
Condition: Ovarian Neoplasm
Intervention:
34 Active, not recruiting Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma
Conditions: Genital Diseases, Female;   Ovarian Diseases;   Ovarian Neoplasms;   Endometrial Neoplasms
Intervention: Drug: Temsirolimus
35 Terminated CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Condition: Ovarian Neoplasms
Interventions: Drug: CAELYX;   Drug: Paclitaxel HCl
36 Completed
Has Results
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Primary Peritoneal Neoplasms
Intervention: Drug: Pegylated L-Asparaginase
37 Active, not recruiting
Has Results
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Condition: Ovarian Neoplasm
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
38 Recruiting Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Conditions: Ovarian Neoplasms;   Ovarian Epithelial Cancer
Interventions: Biological: DCVAC/OvCa with Standard of Care;   Biological: DCVAC/OvCa sequentially chemotherapy;   Drug: Standard of Care
39 Completed Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients
Condition: Ovarian Neoplasms
Intervention: Drug: Carboplatin plus Celecoxib
40 Recruiting Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of Ovary;   Cancer of the Ovary;   Ovary Neoplasms;   Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years